Up to US$200,000 funding per year for each selected proposal, up to 3 years Targeting autoimmune disease, renal disease, pain and neurodegenerative disease, bone disease or platform technologies
13.10.2022 - Asahi Kasei Pharma, subsidiary of diversified Japanese multinational company Asahi Kasei, is publicly calling for new proposals for drug development research as part of its efforts for open innovation to promote pharmaceutical research and . Seite 1